S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end

Becton, Dickinson and Company (BDX) Competitors

$234.12
+0.97 (+0.42%)
(As of 04/19/2024 ET)

BDX vs. DXCM, BSX, RMD, BAX, SYK, WST, MCK, ZTS, EW, and GSK

Should you be buying Becton, Dickinson and Company stock or one of its competitors? The main competitors of Becton, Dickinson and Company include DexCom (DXCM), Boston Scientific (BSX), ResMed (RMD), Baxter International (BAX), Stryker (SYK), West Pharmaceutical Services (WST), McKesson (MCK), Zoetis (ZTS), Edwards Lifesciences (EW), and GSK (GSK). These companies are all part of the "medical" sector.

Becton, Dickinson and Company vs.

Becton, Dickinson and Company (NYSE:BDX) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, community ranking, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

87.0% of Becton, Dickinson and Company shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 0.3% of Becton, Dickinson and Company shares are held by company insiders. Comparatively, 0.4% of DexCom shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, DexCom had 8 more articles in the media than Becton, Dickinson and Company. MarketBeat recorded 18 mentions for DexCom and 10 mentions for Becton, Dickinson and Company. Becton, Dickinson and Company's average media sentiment score of 0.85 beat DexCom's score of 0.80 indicating that Becton, Dickinson and Company is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Becton, Dickinson and Company
7 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
DexCom
9 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Becton, Dickinson and Company has higher revenue and earnings than DexCom. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Becton, Dickinson and Company$19.37B3.49$1.48B$4.2255.48
DexCom$3.62B13.91$541.50M$1.3199.78

Becton, Dickinson and Company presently has a consensus price target of $280.00, indicating a potential upside of 19.60%. DexCom has a consensus price target of $141.40, indicating a potential upside of 8.18%. Given Becton, Dickinson and Company's higher probable upside, equities research analysts clearly believe Becton, Dickinson and Company is more favorable than DexCom.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Becton, Dickinson and Company
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
DexCom
0 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.93

Becton, Dickinson and Company has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500. Comparatively, DexCom has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.

DexCom received 359 more outperform votes than Becton, Dickinson and Company when rated by MarketBeat users. Likewise, 71.99% of users gave DexCom an outperform vote while only 62.25% of users gave Becton, Dickinson and Company an outperform vote.

CompanyUnderperformOutperform
Becton, Dickinson and CompanyOutperform Votes
587
62.25%
Underperform Votes
356
37.75%
DexComOutperform Votes
946
71.99%
Underperform Votes
368
28.01%

DexCom has a net margin of 14.95% compared to Becton, Dickinson and Company's net margin of 6.44%. DexCom's return on equity of 28.31% beat Becton, Dickinson and Company's return on equity.

Company Net Margins Return on Equity Return on Assets
Becton, Dickinson and Company6.44% 13.57% 6.56%
DexCom 14.95%28.31%9.74%

Summary

DexCom beats Becton, Dickinson and Company on 14 of the 19 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BDX vs. The Competition

MetricBecton, Dickinson and CompanySurgical & medical instruments IndustryMedical SectorNYSE Exchange
Market Cap$67.64B$3.75B$4.84B$17.19B
Dividend Yield1.63%2.22%2.93%3.62%
P/E Ratio55.4810.60174.4121.16
Price / Sales3.4955.822,456.859.63
Price / Cash11.5343.2146.2517.06
Price / Book2.634.224.564.85
Net Income$1.48B$4.47M$103.85M$970.56M
7 Day Performance-0.45%-3.81%-4.48%-1.76%
1 Month Performance-1.57%-8.17%-6.67%-3.82%
1 Year Performance-10.61%12.93%7.75%100.03%

Becton, Dickinson and Company Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DXCM
DexCom
4.3783 of 5 stars
$136.52
+1.5%
$141.40
+3.6%
+5.3%$52.63B$3.62B104.219,600Upcoming Earnings
Insider Selling
BSX
Boston Scientific
4.3355 of 5 stars
$68.11
+1.0%
$68.50
+0.6%
+27.3%$99.92B$14.24B63.6548,000Upcoming Earnings
RMD
ResMed
4.8248 of 5 stars
$184.85
-0.1%
$199.20
+7.8%
-19.6%$27.19B$4.22B30.5510,140Upcoming Earnings
News Coverage
BAX
Baxter International
4.8865 of 5 stars
$39.56
-1.2%
$46.30
+17.0%
-9.5%$20.09B$14.81B7.5860,000Short Interest ↓
SYK
Stryker
4.7805 of 5 stars
$337.54
-0.5%
$339.22
+0.5%
+8.7%$128.42B$20.50B40.9152,000
WST
West Pharmaceutical Services
4.7862 of 5 stars
$379.48
+0.2%
$435.20
+14.7%
+1.2%$27.78B$2.95B48.1610,600Upcoming Earnings
Analyst Revision
News Coverage
MCK
McKesson
4.7648 of 5 stars
$528.42
+1.1%
$533.50
+1.0%
+47.6%$69.44B$276.71B23.9451,000
ZTS
Zoetis
4.7951 of 5 stars
$153.02
+2.2%
$221.75
+44.9%
-16.3%$69.99B$8.54B30.1814,100Analyst Report
Insider Selling
EW
Edwards Lifesciences
4.4233 of 5 stars
$90.06
+1.0%
$91.73
+1.9%
-0.6%$54.21B$6.00B39.1619,800Upcoming Earnings
Analyst Revision
News Coverage
GSK
GSK
2.678 of 5 stars
$39.95
-1.4%
N/A+7.6%$82.78B$37.71B13.2770,200

Related Companies and Tools

This page (NYSE:BDX) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners